Evidence map›Paper›PMID 35599263›Full record

ArticleMedical oncology (Northwood, London, England)2022

The effects of Epigallocatechin-3-gallate and Dabrafenib combination on apoptosis and the genes involved in epigenetic events in anaplastic thyroid cancer cells.

Nihal Birden, Nur Selvi Gunel, Neslihan Pinar Ozates, Bakiye Goker Bagca, Cumhur Gunduz, Leila Sabour Takanlou, Maryam Sabour Takanlou, Cigir Biray Avci

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Reprogramming of fatty acid metabolism in thyroid cancer: Potential targets and mechanisms.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025
    Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Nihal BirdenDepartment of Medical Biology, Faculty of Medicine, Ege University, Bornova, 35100, Izmir, Turkey.
Nur Selvi GunelDepartment of Medical Biology, Faculty of Medicine, Ege University, Bornova, 35100, Izmir, Turkey.
Neslihan Pinar OzatesDepartment of Medical Biology, Faculty of Medicine, Ege University, Bornova, 35100, Izmir, Turkey.
Bakiye Goker BagcaDepartment of Medical Biology, Faculty of Medicine, Ege University, Bornova, 35100, Izmir, Turkey.
Cumhur GunduzDepartment of Medical Biology, Faculty of Medicine, Ege University, Bornova, 35100, Izmir, Turkey.
Leila Sabour TakanlouDepartment of Medical Biology, Faculty of Medicine, Ege University, Bornova, 35100, Izmir, Turkey.
Maryam Sabour TakanlouDepartment of Medical Biology, Faculty of Medicine, Ege University, Bornova, 35100, Izmir, Turkey.
Cigir Biray AvciDepartment of Medical Biology, Faculty of Medicine, Ege University, Bornova, 35100, Izmir, Turkey. cbavci@gmail.com.ORCID http://orcid.org/0000-0001-8251-4520
Ege University · TR

Funding

Ege Üniversitesi TYL-2019-20389
6 · The paper itself

Abstract

Anaplastic thyroid cancer cases with poor prognosis are associated with epigenetic modifications such as abnormal DNA methylation. Epigallocathesin-3-gallate (EGCG) is a polyphenol compound of green tea that is still under investigation on its role in cancer prevention. EGCG is known as an epigenetic diet in DNA methyltransferase inhibitor. The cytotoxic effects of Dabrafenib, EGCG, and dabrafenib in combination with EGCG were assessed by using WST-8 assay; and also, Flow cytometry was utilized to identify cells undergoing apoptosis after treatments of the SW-1736 cells. We investigated the mRNA expression of genes involved in epigenetic events in SW-1736 cells by real-time qRT-PCR following the treatments. We demonstrated for the first time that the Dabrafenib-EGCG combination reduced cell viability significantly depending on concentration and induced apoptosis by 8.49-fold through investigating the additive effect together on SW-1736 cells. The IC

Indexed as

CatechinThyroid Carcinoma, AnaplasticThyroid NeoplasmsApoptosisCell Line, TumorEpigenesis, GeneticHumansImidazolesOximesCatechindabrafenibepigallocatechin gallateImidazolesOximesAnaplastic thyroid cancerApoptosisBRAFDabrafenibEpigenetic

Identifiers

PMID35599263
OpenAlexW4281297586

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.